Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 38
- Registration Number
- NCT02147431
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Healthy
- Interventions
- Drug: placebo
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 44
- Registration Number
- NCT02146079
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
Phase 3
Completed
- Conditions
- Haemophilia BCongenital Bleeding Disorder
- Interventions
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 54
- Registration Number
- NCT02141074
- Locations
- 🇦🇹
Landes-Frauen und Kinderklinik Linz, Linz, Austria
🇦🇹LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde, Salzburg, Austria
🇺🇸Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 124
- Registration Number
- NCT02137850
- Locations
- 🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
🇺🇸Arizona H&T Phoenix Child Hosp, Phoenix, Arizona, United States
🇺🇸Rush University Med. Cntr, Chicago, Illinois, United States
A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT02131246
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
Phase 3
Terminated
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT02131272
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Kayseri, Turkey
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1089
- Registration Number
- NCT02128932
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Taunton, United Kingdom
A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India
Completed
- Conditions
- Diabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1056
- Registration Number
- NCT02117622
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Thriruvananthapuram, India
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 31
- Registration Number
- NCT02100475
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valencia, Spain
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- Drug: placebo
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 835
- Registration Number
- NCT02098395
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Örebro, Sweden
© Copyright 2025. All Rights Reserved by MedPath